EUVIMEDEUVIMED entdecken
Crossref

Effectiveness and Safety of Selective Serotonin Reuptake Inhibitors in Individuals with Williams Syndrome

Liron Snapir iD, Maya Elazar, Tal Cohen, Ronnie Weinberger, Maya Schwartz-Lifshitz, Michal Taler, Doron Gothelf

Journal of Child and Adolescent Psychopharmacology · 01.08.2026 · 36 (6) · 377-381

DOI: 10.1177/10445463261451798 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Child and Adolescent Psychopharmacology, online erschienen am 13.05.2026. Verfasst von Liron Snapir und 6 weiteren Autor:innen. Beteiligte Einrichtung: The Department of Child and Adolescent Psychiatry, Behavioral Neurogenetics Center, Edmond and Lily Safra Children's Hospital, Sheba Medical Center, …. Hauptthemen laut MEDLINE: Selective Serotonin Reuptake Inhibitors, Williams Syndrome, Depressive Disorder, Anxiety Disorders. Die Arbeit nennt 23 Literaturangaben. Gefördert von: Autour des Williams association.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Anxiety and depressive disorders are common in individuals with Williams syndrome (WS), yet data regarding pharmacologic treatment in this population are limited. This study aimed to evaluate the effectiveness and safety of selective serotonin reuptake inhibitors (SSRIs) in individuals with WS treated for anxiety and/or depressive disorders.

Methods

We conducted a retrospective chart review of patients with a genetically confirmed diagnosis of WS treated with SSRIs between 2010 and 2025 at a clinic for individuals with WS. Fourteen children and adults (5 males and 9 females; mean age: 23.2 ± 11.9 years) met inclusion criteria, contributing 16 distinct SSRI treatment trials. Illness severity was assessed using the Clinical Global Impressions–Severity (CGI-S) scale at baseline and last follow-up and the Clinical Global Impressions–Improvement (CGI-I) scale.

Results

The CGI-S score decreased significantly from 4.62 ± 0.81 at baseline to 3.06 ± 1.12 at last follow-up ( t (15) = 3.83, p = 0.002). Nine of 16 trials (56.2%) were rated as much or very much improved (CGI-I = 1 or 2). The mean duration of SSRI treatment was 3.95 ± 3.91 years (range: 0.75–16). Adverse events were documented in two trials (12.5%), and no treatment discontinuations due to adverse events occurred.

Conclusions

SSRI treatment was effective and well tolerated in individuals with WS. Prospective controlled studies are required.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Selective Serotonin Reuptake InhibitorsWilliams SyndromeDepressive DisorderAnxiety DisordersHumansFemaleMaleChildRetrospective StudiesAdolescentAdultYoung AdultTreatment OutcomeSeverity of Illness IndexPsychiatric Status Rating ScalesFollow-Up Studies

Stichwörter der Autor:innen

Williams syndromeanxiety disordersdepressive disorderspsychopharmacologyselective serotonin reuptake inhibitors

Substanzen

Selective Serotonin Reuptake Inhibitors

Autor:innen und Institutionen

  • The Department of Child and Adolescent Psychiatry, Behavioral Neurogenetics Center, Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Tel Hashomer, Israel.
  • Gray Faculty of Medical & Health Sciences, Tel Aviv University, Tel Aviv, Israel.
  • Pediatric Molecular Psychiatry Laboratory, Sheba Medical Center, Tel Hashomer, Israel.
  • Sagol School of Neuroscience, Tel Aviv University, Tel Aviv, Israel.

ORCID-Profile: Liron Snapir

Förderung

  • Autour des Williams association

Zitieren

APA

Snapir, L., Elazar, M., Cohen, T., Weinberger, R., Schwartz-Lifshitz, M., Taler, M., & Gothelf, D. (2026). Effectiveness and Safety of Selective Serotonin Reuptake Inhibitors in Individuals with Williams Syndrome. Journal of Child and Adolescent Psychopharmacology, 36(6), 377-381. https://doi.org/10.1177/10445463261451798

Vancouver

Snapir L, Elazar M, Cohen T, Weinberger R, Schwartz-Lifshitz M, Taler M, et al. Effectiveness and Safety of Selective Serotonin Reuptake Inhibitors in Individuals with Williams Syndrome. Journal of Child and Adolescent Psychopharmacology. 2026;36(6):377-381. doi:10.1177/10445463261451798

BibTeX
@article{Snapir2026,
  author = {Snapir, Liron and Elazar, Maya and Cohen, Tal and Weinberger, Ronnie and Schwartz-Lifshitz, Maya and Taler, Michal and Gothelf, Doron},
  title = {Effectiveness and Safety of Selective Serotonin Reuptake Inhibitors in Individuals with Williams Syndrome},
  journal = {Journal of Child and Adolescent Psychopharmacology},
  year = {2026},
  volume = {36},
  number = {6},
  pages = {377--381},
  doi = {10.1177/10445463261451798}
}
Kostenlos starten →